Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Leclerc

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Bioorganic & Medicinal Chemistry Letters|September 20, 2011
Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitorsJean-Philippe Leclerc, Jean-Pierre Falgueyret, Mélina Girardin, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2011
Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitorsYeeman K Ramtohul, David Powell, Jean-Philippe Leclerc, et al.
Bioorganic & Medicinal Chemistry Letters|January 3, 2012
Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine seriesNicolas Lachance, Yves Gareau, Sébastien Guiral, et al.
ACS Medicinal Chemistry Letters|December 18, 2020
Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1α Inhibitory ActivityRamsay E Beveridge, Heidi Ackerly Wallweber, Avi Ashkenazi, et al.
Journal of Medicinal Chemistry|May 15, 2024
Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma ModelMarie-Gabrielle Braun, Avi Ashkenazi, Ramsay E Beveridge, et al.
ACS Medicinal Chemistry Letters|September 22, 2023
Discovery of Selective Tertiary Amide Inhibitors of Cyclin-Dependent Kinase 2 (CDK2)Mingshuo Zeng, Jessica M Grandner, Marian C Bryan, et al.
ACS Medicinal Chemistry Letters|June 17, 2026
Optimization and <i>In Vivo</i> Characterization of a Series of Cbl‑b Inactive-State InhibitorsMichael J Lambrecht, Jun Liang, Peter Man-Un Ung, et al.
Bioorganic & Medicinal Chemistry Letters|July 17, 2019
Design of a brain-penetrant CDK4/6 inhibitor for glioblastomaSarah M Bronner, Karl A Merrick, Jeremy Murray, et al.
ACS Medicinal Chemistry Letters|June 19, 2024
Optimization of a Novel DEL Hit That Binds in the Cbl-b SH2 Domain and Blocks Substrate BindingJun Liang, Michael J Lambrecht, Teresita L Arenzana, et al.
ACS Medicinal Chemistry Letters|June 17, 2026
Optimization Leading to a Potent and Selective Cbl‑b Inactive-State Inhibitor That Demonstrated <i>In Vivo</i> EfficacyJun Liang, Michael J Lambrecht, Malcolm P Huestis, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Bioorganic & Medicinal Chemistry Letters|September 20, 2011
Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitorsJean-Philippe Leclerc, Jean-Pierre Falgueyret, Mélina Girardin, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2011
Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitorsYeeman K Ramtohul, David Powell, Jean-Philippe Leclerc, et al.
Bioorganic & Medicinal Chemistry Letters|January 3, 2012
Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine seriesNicolas Lachance, Yves Gareau, Sébastien Guiral, et al.
ACS Medicinal Chemistry Letters|December 18, 2020
Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1α Inhibitory ActivityRamsay E Beveridge, Heidi Ackerly Wallweber, Avi Ashkenazi, et al.
Journal of Medicinal Chemistry|May 15, 2024
Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma ModelMarie-Gabrielle Braun, Avi Ashkenazi, Ramsay E Beveridge, et al.
ACS Medicinal Chemistry Letters|September 22, 2023
Discovery of Selective Tertiary Amide Inhibitors of Cyclin-Dependent Kinase 2 (CDK2)Mingshuo Zeng, Jessica M Grandner, Marian C Bryan, et al.
ACS Medicinal Chemistry Letters|June 17, 2026
Optimization and <i>In Vivo</i> Characterization of a Series of Cbl‑b Inactive-State InhibitorsMichael J Lambrecht, Jun Liang, Peter Man-Un Ung, et al.
Bioorganic & Medicinal Chemistry Letters|July 17, 2019
Design of a brain-penetrant CDK4/6 inhibitor for glioblastomaSarah M Bronner, Karl A Merrick, Jeremy Murray, et al.
ACS Medicinal Chemistry Letters|June 19, 2024
Optimization of a Novel DEL Hit That Binds in the Cbl-b SH2 Domain and Blocks Substrate BindingJun Liang, Michael J Lambrecht, Teresita L Arenzana, et al.
ACS Medicinal Chemistry Letters|June 17, 2026
Optimization Leading to a Potent and Selective Cbl‑b Inactive-State Inhibitor That Demonstrated <i>In Vivo</i> EfficacyJun Liang, Michael J Lambrecht, Malcolm P Huestis, et al.
Pageof 6